Pharmaceutical

Navigator gains $100m in Series A funding for antibody therapeutics

Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.

Aug 29, 2024 - 04:00
Navigator gains $100m in Series A funding for antibody therapeutics
Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.
Read the original article

Tags:

Previous Article

Oesophageal cancer: the global clinical trials landscape in 2024

Next Article

EC approves Astellas’ PADCEV for urothelial cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

Alvotech’s AVT05 in phase III rheumatoid arthritis stud...

Sep 23, 2023

STAT+: ALS patients support bill that could help patients with other rare diseases

STAT+: ALS patients support bill that could help patien...

Oct 26, 2023

STAT+: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting

STAT+: FDA finds ‘potential systemic bias’ in Amgen’s K...

Oct 4, 2023